Drug Approval | July 26, 2023
Eugia Pharma receives USFDA approval for Plerixafor Injection
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The drug will be available in 600 hospitals and 105 DTPs
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Subscribe To Our Newsletter & Stay Updated
